GNTA News and Press, Genenta Science S.p.A. From 11/07/22

• Signs of intra-tumor pro-inflammatory state in patients • Temferon™ induced immune system reset in preclinical studies • Macrophage and T cell profiles in patients’ tumor microenvironment echo preclinical findings MILAN, Italy and NEW YORK, Nov. ...

Genenta Science press release ( NASDAQ: GNTA ): 1H GAAP EPS of €0.27 beats by €0.42 . Cash and cash equivalents of €34.7 million as of June 30, 2022. €1.8 million unrealized foreign exchange gain. For further details see: ...

Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimen Cash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024...

MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors...

Genenta Sciences (NASDAQ: GNTA) is a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Their platform is not tumor type nor target antigen res...

The following slide deck was published by Genenta Science S.p.A. in conjunction with this event. For further details see: Genenta Science (GNTA) Investor Presentation - Slideshow

MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumor...

H.C. Wainwright has initiated stem cell gene therapy developer Genenta Science ( NASDAQ: GNTA ) as a buy seeing promise for the company's technology providing advantages differentiating elements over other cellular therapies for cancer. The firm has a $25 price target (269...

MILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in their interactions with U.S. financial markets and investors. BGB will function as ...

Gainers: Endo International plc (ENDP) +95%. Agile Therapeutics (AGRX) +66%. Kezar Life Sciences (KZR) +53%. Decibel Therapeutics (DBTX) +25%. Ceragon Networks (CRNT) +23%. InflaRx (IFRX) +20%. Sutro Biopharma (STRO) +19%. Tyra Biosciences (TYRA) +17%. Oasis Petroleum (OAS) +16%. Biotricity (...